Gas chromatography-mass spectrometry assay method for the therapeutic drug monitoring of the antiepileptic drug tiagabine

Journal of Pharmaceutical and Biomedical Analysis

Volumn 21, Issue 3, 1999, Pages 641-646

  Chollet, D F ^a   Castella, E ^a   Goumaz, L ^a   Anderegg, G ^a  

^a Rue M Marcinhes 7 CH 1217 ^*  (Switzerland)

Author keywords

Antiepileptic drugs; GC MS; Human serum; Therapeutic drug monitoring; Tiagabine

Indexed keywords

ANTICONVULSIVE AGENT; DRUG METABOLITE; NORTIAGABINE; TIAGABINE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TECHNIQUE;

ANTICONVULSANTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; NIPECOTIC ACIDS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 0032712339     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(99)00167-3     Document Type: Article

References (9)

1. Snel S., Jansen J.A., Mengel H.B., Richens A., Larsen S. J. Clin. Pharmacol. 37:1997;1015-1020.
2. Mengel H. Epilepsia. 35(Suppl. 5):1994;S81-S84.
3. Crossley R. Crossley R. Chirality and the Biological Activity of Drugs. 1995;136-137 CRC Press, New York.
4. D. Chollet, L. Balant, J. Chromatogr. B, (1999) in prepartion.
5. Gustavson E., Chu Sou-yie J. Chromatogr. B. 574:1992;313-318.
6. Directive 75/316/EEC, CPMP Working Party, Tests on Samples of Biological Origin, ref. III/844/87 final (August 1989).
7. N. Wad, Swiss Center for Epilepsy, Zürich, Switzerland, unpublished results.
8. Chollet D., Bibas P., Arnera V., Lanz R. J. Chromatogr. B. 707:1998;334-337.
9. Hashimoto N., Ayoama T., Shioiki T. Chem. Pharm. Bull. 29:1981;1475-1478.